Clinical trials: Non Alcoholic Fatty Liver
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Non-alcoholic Steatohepatitis
Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin
This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin disposition to differences in the bile acid…
- Trial name
- NCT02235233
- Testing
- Technetium Tc 99M Mebrofenin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
T2DM (Type 2 Diabetes Mellitus), Fatty Liver
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
- Trial name
- ALT (NCT03233178)
- Testing
- Non-interventional
- Where
- Canada
- Volunteers
- 4,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Fatty Liver
Fatty Liver Response of Cardio-metabolic Risk Factors to Laser Acupuncture Versus Cupping
Every-two-week applied cupping (with scarification) session within one month on back of upper thorax is not compared previously regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints…
- Trial name
- NCT04971434
- Testing
- laser stimulation for acupoints, cupping with scarification
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Non-Alcoholic Steatohepatitis
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02787304
- Testing
- SHP626
- Where
- 65 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
This is an multicenter, randomized, double-blind, parallel-controlled study to evaluated the efficacy of pioglitazone hydrochloride and metformin hydrochloride tablets on the patients with newly diagnosed type 2 diabetes mellitus…
- Conditions
- Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy
- Trial name
- NCT03796975
- Testing
- Combination of Pioglitazone and Metformin Tablets, Metformin Hydrochloride Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD…
- Trial name
- NCT01030484
- Where
- 8 sites in United States
- Volunteers
- 2,501 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Effect of Indian Hepatoprotective Diet in Reversibility of NAFLD
The modality of lifestyle modification including low calorie diets along with normal protein and moderate physical activity is the safest standard medical treatment for NAFLD in general.
- Trial name
- NAFLDNutrition (NCT05696808)
- Testing
- IHPD, Western Diet
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Weight Loss, NAFLD
YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
This study is for men and women have been diagnosed with non-alcoholic fatty liver disease (NAFLD) and will consequently participate in the YMCA's Diabetes Prevention Program.
- Conditions
- Weight Loss, NAFLD, Liver Diseases
- Trial name
- NCT03512184
- Testing
- YMCA class
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Weill Medical College of Cornell University
Non-alcoholic Fatty Liver Disease (NAFLD)
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2.
- Trial name
- NCT00375349
- Testing
- Ultrasound to demonstrate existence of fatty liver
- Sponsor
- Shaare Zedek Medical Center
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
NASH - Nonalcoholic Steatohepatitis
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment
- Trial name
- NCT04321343
- Testing
- PXL065
- Where
- 29 sites in United States
- Volunteers
- 117 people
- Sponsor
- Poxel SA
NAFLD, NASH - Nonalcoholic Steatohepatitis
Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients
Due to the limited data concerning Egyptian population. authors aimed to investigate the differentadipokine gene polymorphism related to non alcoholic fatty liver disease incidence, prognosis and progression to steotosis and also…
- Trial name
- NCT04561895
- Testing
- DNA extraction
- Where
- Egypt
- Volunteers
- 224 people
- Sponsor
- Cairo University
NAFLD
Non-alcoholic Fatty Liver Disease and Its Treatment
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT05480007
- Testing
- sitagliptin and metformin, Sitagliptin, Metformin
- Volunteers
- 68 people
- Sponsor
- Shanghai 10th People's Hospital
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by…
- Trial name
- FLINT (NCT01265498)
- Testing
- obeticholic acid
- Where
- 9 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Depressive Disorder, Depression
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
The trial will be a four-arm, parallel group, prospective, randomized, double-blind, controlled design that will include 200 participants and will last 20 weeks.
- Conditions
- Depressive Disorder, Depression, Anxiety, Stress
- Trial name
- PRO-DEMET (NCT04756544)
- Testing
- Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Lodz
Polycystic Ovarian Syndrome,, Nonalcoholic Fatty Liver Disease
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS
Since both pathologies (PCOS and NAFLD) involve disturbed carbohydrate economy, which revolve around insulin resistance, it is tempting to examine the specific "liver profile" of women with PCOD.
- Trial name
- NCT01735799
- Where
- Israel
- Sponsor
- Assy Nimer
Cardiovascular Disease
The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health
The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease
- Trial name
- Almonds (NCT02907684)
- Testing
- Almonds, Muffins/Crackers
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- King's College London
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.